Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature-Reference-Cited by-同舟云学术

Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature

Published:2017 Issue:3 Volume:4 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Shields Ryan K.¹²,Nguyen M. Hong¹²,Press Ellen G.¹,Chen Liang³,Kreiswirth Barry N.³,Clancy Cornelius J.¹²⁴

Affiliation:

1. Department of Medicine, University of Pittsburgh, Pennsylvania

2. XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pennsylvania

3. Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark;and

4. VA Pittsburgh Healthcare System, Pennsylvania

Abstract

Abstract We used meropenem to successfully treat a patient with bacteremia due to ceftazidime-avibactam-resistant, meropenem- susceptible Klebsiella pneumoniae that carried mutant blaKPC-3. Meropenem was bactericidal against ceftazidime-avibactam- resistant K pneumoniae isolates in vitro. Nevertheless, the role of carbapenems in treating such infections remains uncertain, because meropenem resistance is selected readily during passage experiments.

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/article-pdf/4/3/ofx101/33622905/ofx101.pdf

Reference10 articles.

1. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections;Shields;Antimicrob Agents Chemother,2017

2. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection;Jaruratanasirikul;Antimicrob Agents Chemother,2005

3. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections;Shields;Clin Infect Dis,2016

4. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms;Temkin;Antimicrob Agents Chemother,2017

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients;Journal of Antimicrobial Chemotherapy;2024-08-19

2. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

3. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis;Emerging Microbes & Infections;2024-06-04

4. Comparison of ERIC carbapenem-resistant Enterobacteriaceae test, BD Phoenix CPO detect panel, and NG-test CARBA 5 for the detection of main carbapenemase types of carbapenem-resistant Enterobacterales;Journal of Microbiology, Immunology and Infection;2024-06

5. Detection of KPC-216, a Novel KPC-3 Variant, in a Clinical Isolate of Klebsiella pneumoniae ST101 Co-Resistant to Ceftazidime-Avibactam and Cefiderocol;Antibiotics;2024-05-29